Plant, Animal and Human Genome Editing and Genetic Engineering

Kirsten Ellegaard^*
*Correspondence: Kirsten Ellegaard, Department of Genitics, University of Statens Serum, Copenhagen, Denmark, Email:

Keywords

Mitigating threats • Genetic disorders • Meat production

Introduction

The application of genome editing in humans, often referred to as gene therapy, holds transformative potential for the treatment of genetic disorders. By precisely modifying or correcting genetic sequences associated with diseases, researchers aim to develop curative therapies. CRISPR-Cas9, in particular, has emerged as a powerful tool for human genome editing, offering the ability to target specific genes with unprecedented accuracy. Clinical trials are underway to explore the therapeutic potential of gene editing for conditions like sickle cell anemia, cystic fibrosis, and certain types of cancers. However, the application of genome editing in humans raises complex ethical, social, and safety considerations. Questions about the long-term effects, unintended consequences, and the potential for germline editing, which could impact future generations, demand thoughtful reflection and stringent regulatory frameworks. The ethical dimensions surrounding the potential misuse of these technologies, such as designer babies or enhancements beyond medical necessity, necessitate on-going dialogue and international cooperation.

Literature Review

We used a multi-step methodology that combined information from various genomic sources and databases, such as protein-protein interaction networks, gene expression profiling, and pathway analysis. We discovered 14 genes through this thorough analysis that provided strong support for their pathogenesis-related roles in endometriosis. These genes were prioritized based on their functional relationships and enrichment in immune and metabolic pathways. Our integrative genomic analyses highlighted the 14 prioritized genes' interconnectedness, forming a strong network that is thought to be involved in the emergence of endometriosis. Additionally, pathway enrichment analysis of these genes revealed a notable overrepresentation of metabolic and immune-related pathways, shedding light on the underlying biological mechanisms that are disrupted in endometriosis. These results supported the idea that changes to immune and metabolic pathways play critical roles in the [1].

Discussion

In all three domains plants, animals, and humans, the advent of genome editing technologies demands a delicate balance between scientific progress, ethical considerations, and responsible stewardship. Collaborative efforts among scientists, policymakers, ethicists, and the public are essential to navigating the evolving landscape of genetic engineering. Establishing robust regulatory frameworks, fostering transparency in research, and ensuring equitable access to the benefits of these technologies are crucial steps toward harnessing their potential for the betterment of society while mitigating potential risks. The responsible and inclusive advancement of genome editing technologies has the potential to reshape agriculture, medicine, and conservation, offering both unprecedented opportunities and ethical challenges that must be navigated with care and foresight [2].

The application of genome editing technologies raises broader societal considerations beyond individual species or organisms. The ability to modify the genetic makeup of plants, animals, and humans has implications for ecosystems, biodiversity, and the delicate balance of nature. In agriculture, for instance, the deployment of genetically modified crops may influence local ecosystems and impact non-target organisms, raising concerns about unintended ecological consequences. Striking a balance between agricultural innovation and environmental sustainability is essential to ensure the responsible use of genetic engineering in plants. In the realm of animals, ethical questions emerge concerning the welfare and rights of genetically modified organisms. As technologies advance, the creation of animals with specific traits or modifications prompts discussions about the ethical treatment of these creatures. The potential use of genetic engineering for purposes such as creating exotic pets or novel aesthetic traits in animals demands careful ethical scrutiny, considering the well-being of the modified organisms and the potential impact on ecosystems [3,4].

The application of genome editing in humans not only holds promise for addressing genetic diseases but also introduces ethical considerations related to equity, access, and consent. The potential for designer babies or the enhancement of certain traits may raise concerns about creating genetic disparities and exacerbating existing social inequalities. Additionally, the global community faces the challenge of establishing international norms and regulations to govern the ethical use of gene editing technologies, ensuring that these powerful tools are deployed responsibly and for the benefit of all. Public awareness and engagement are crucial components of navigating the ethical landscape of genome editing. Open and inclusive dialogues involving scientists, ethicists, policymakers, and the general public can help establish shared values, ethical guidelines, and societal consensus on the acceptable uses of these technologies. Ethical considerations should be integrated into the research and development processes, and regulatory frameworks must be adaptive to keep pace with rapidly evolving scientific capabilities [5,6].

Conclusion

Genome editing and genetic engineering are transformative technologies with the potential to revolutionize agriculture, medicine, and conservation efforts. However, the ethical dimensions inherent in modifying the genetic fabric of plants, animals, and humans demand careful and considered exploration. Balancing scientific innovation with ethical principles, environmental sustainability, and societal values is essential for ensuring that the benefits of genome editing are realized responsibly and equitably. As these technologies continue to advance, a collaborative and ethically informed approach will be paramount to harnessing their potential for positive impact while mitigating potential risks and ensuring a just and sustainable future.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Helbig, Ingo, Ingrid E. Scheffer, John C. Mulley and Samuel F. Berkovic. "Navigating the channels and beyond: Unravelling the genetics of the epilepsies." Lancet Neurol 7 (2008): 231-245.

   Google Scholar, Crossref, Indexed at

2. Appelbaum, Mathis and Thomas Schweder. "Metabolic engineering of bacillusâ??new tools, strains and concepts." Metab Eng 13 (2021): 469-518.

   Google Scholar, Crossref, Indexed at

3. De Magalhaes, Joao Pedro, Arie Budovsky, Gilad Lehmann and Joana Costa, et al. "The Human Ageing Genomic Resources: Online databases and tools for biogerontologists." Aging cell 8 (2009): 65-72.

   Google Scholar, Crossref, Indexed at

4. Malanchini, Margherita, Kaili Rimfeld, Nicholas G. Shakeshaft and Maja Rodic, et al. "The genetic and environmental aetiology of spatial, mathematics and general anxiety." Sci Rep 7 (2017): 1-11.

   Google Scholar, Crossref, Indexed at

5. Goldman, David, Gabor Oroszi and Francesca Ducci. "The genetics of addictions: Uncovering the genes." Focus 6 (2006): 521-415.

   Google Scholar, Crossref, Indexed at

6. Kapoor, Rahul and Thomas Klueter. "Decoding the adaptabilityâ??rigidity puzzle: Evidence from pharmaceutical incumbents’ pursuit of gene therapy and monoclonal antibodies." Acad Manag J 58 (2015): 1180-1207.

   Google Scholar, Crossref, Indexed at